A 47-year-old man came in for what he described as a sexual wellness consultation. The complaint was new-onset erectile dysfunction over the past eight months. He was an active duty soldier at Fort Benning, ran four miles three times a week, was within fifteen pounds of his Army weight, and had what he considered an unremarkable medical history. His primary care provider had written him a prescription for sildenafil and sent him on his way. The medication worked, mostly, and he was here because he wanted to know whether anything else could be done.
I asked him about his last cardiovascular workup. He could not remember whether he had ever had one. I drew the lab panel I always draw on a man with new-onset ED, and three weeks later we sat down with the results. His fasting insulin was 18 mIU/L. His triglyceride-to-HDL ratio was 4.1. His hs-CRP was 4.2 mg/L. His total testosterone was 312 ng/dL. He had silent metabolic syndrome and early endothelial dysfunction, and his ED was not a sexual problem — it was a vascular problem presenting in the smallest, most pressure-sensitive vascular bed in his body.
I spent seventeen years in emergency medicine, cardiac ICU, and the cath lab before I built this practice. I have watched hundreds of men come through the doors of an ED department with a first heart attack who, when you took a careful history, had been losing erectile function for two to five years before the cardiac event. The penis is a vascular organ. When the small arteries stop doing their job, the penis is one of the first places it shows up. It is the canary in the cardiovascular coal mine.
Why erectile function fails before the heart does
The mechanism is not subtle once you understand the plumbing. An erection requires the cavernosal arteries to dilate — driven by nitric oxide release from healthy endothelium — and the smooth muscle of the corpus cavernosum to relax, allowing blood to fill the sinusoidal spaces. The veins that drain the penis are then mechanically compressed against the tunica albuginea, trapping blood and producing rigidity. The whole process depends on healthy endothelium, healthy smooth muscle, intact autonomic nerve signaling, and adequate testosterone to maintain the receptor and tissue environment.
The cavernosal arteries are roughly 1 to 2 millimeters in diameter. The coronary arteries are 3 to 4 millimeters. The carotids are 5 to 7 millimeters. When systemic endothelial dysfunction begins — when the inner lining of the arteries starts producing less nitric oxide and more inflammatory signaling — the smallest vessels are the first to show clinical compromise. The cavernosal arteries lose their dilatory capacity years before the coronary arteries narrow enough to produce angina. That lag time is your warning window.
The data on this is consistent. Men with ED have a roughly two-fold increased risk of major adverse cardiovascular events over the following five to ten years, independent of traditional risk factors. The lead time between onset of ED and a first cardiac event in published cohorts averages around three to five years. New-onset ED in a man under 60 should be treated as a cardiovascular evaluation trigger, not just a sexual wellness complaint. In my practice it is, every time.
What I look for on the workup
When a man comes in with ED, the panel I draw is broader than what most primary care offices run. The comprehensive lab work includes total and free testosterone, SHBG, estradiol, LH, FSH, prolactin, full thyroid panel, fasting insulin, HbA1c, fasting glucose, advanced lipid panel including ApoB and Lp(a), hs-CRP, fibrinogen, homocysteine, vitamin D, and a full metabolic panel. I am not running these tests because they all matter to ED specifically. I am running them because they all matter to cardiovascular risk, and ED in a mid-life man is a cardiovascular risk evaluation.
The patterns I see most often:
Insulin resistance. Fasting insulin above 10 mIU/L and a triglyceride-to-HDL ratio above 2 are the most common findings in mid-life ED patients. Insulin resistance impairs endothelial nitric oxide production directly, suppresses SHBG (which lowers free testosterone), and drives the visceral adiposity that is itself a hormonally active organ producing inflammatory cytokines. The man with ED and insulin resistance has a metabolic problem that is producing both his sexual symptom and his future cardiac risk.
Low testosterone with high SHBG. The total testosterone may look acceptable on paper while the bioavailable fraction is at the floor. Free testosterone under 65 pg/mL routinely produces ED even when total testosterone reads 450 ng/dL. The receptor cannot do its job with what is available.
Subclinical hypothyroidism. TSH above 2.5 with low-normal free T3, or elevated reverse T3, suppresses libido, energy, and the hypothalamic-pituitary-gonadal axis. A meaningful percentage of ED patients have a thyroid contributor that has never been worked up.
Not sure where to start?
The Start Here pathway walks you through the most common entry points and helps you decide which consultation type is the right fit. Five minutes of self-assessment can save you a wrong-direction conversation.
Elevated inflammatory markers. hs-CRP above 2 mg/L, elevated fibrinogen, or elevated homocysteine are independent markers of endothelial dysfunction. These do not get measured on a standard primary care panel, and they often tell the most useful story.
The physical exam matters too. Blood pressure, waist circumference, peripheral pulses, a careful skin and nail exam for signs of peripheral vascular disease. None of this takes long. All of it is more informative than handing a man a prescription for a PDE5 inhibitor and telling him to come back if it stops working.
Why "just take the pill" misses the point
Sildenafil and tadalafil work for most men with ED, at least initially, and I prescribe them. They are good drugs. But they treat the downstream symptom by inhibiting the enzyme that breaks down cyclic GMP, prolonging the nitric oxide-driven vasodilation that an aging endothelium can no longer sustain on its own. They do not fix the endothelium. They do not address insulin resistance. They do not raise testosterone. They do not lower the man's risk of a cardiac event in five years.
The conventional approach in primary care — write the prescription, refill as needed, never pull the labs — is convenient for the visit and misses the actual clinical opportunity. The patient who comes in at 47 with new ED is showing you a window into his cardiovascular trajectory. Treating only the erectile complaint is the equivalent of unscrewing the chest pain warning light because it was annoying. The light was telling you something.
For Erectile Dysfunction Treatment in my practice, the framework is different. Yes, we address the symptom — PDE5 inhibitors, occasionally a PRP-based regenerative approach when tissue quality is the issue, sometimes a combination protocol. But the symptom treatment runs in parallel with addressing the underlying vascular and metabolic picture, because that is what produces durable improvement and reduces downstream risk.
How I structure the treatment plan
The plan I build depends on what the labs reveal. If insulin resistance is present, we address it directly — often with a structured medical weight loss approach including GLP-1 therapy when indicated, alongside specific nutritional and resistance training guidance. If testosterone is genuinely low and the picture supports replacement, men's testosterone replacement becomes part of the plan. The route matters here — injection, cream, or Biote pellet therapy — and the right choice depends on the patient's lifestyle, sensitivity to fluctuations, and preference. For a soldier or first responder with unpredictable schedules, pellets often work better than weekly injections.
If the inflammatory picture is elevated, we address the drivers — sleep, stress, visceral fat, dietary patterns — and recheck the markers at three months. If thyroid is contributing, we treat the thyroid. If the labs are largely clean and the issue is genuinely a focal vascular or tissue issue, regenerative approaches become more relevant.
The PDE5 inhibitor stays available throughout. I am not interested in withholding effective symptomatic treatment while the underlying picture is being addressed. The point is not either-or. The point is treating the cardiovascular picture so that ten years from now the patient is not the one I used to see in the cath lab.
What I tell the patient at the lab review
The conversation I have with a man at the lab review covers three things. First: your ED is real, it is treatable, and the medication will work for the symptom while we address the rest. Second: your labs show specific findings — and I walk through them — that put you at meaningfully elevated cardiovascular risk over the next five to ten years if not addressed. Third: the same protocol that improves your ED is the same protocol that lowers your cardiac risk, and we are going to do both at once.
The men who hear this message and engage with it tend to do well. They get the symptomatic improvement they came in for, and they get a five- or ten-year risk reduction that they did not know they needed. The men who decline the broader workup and just want the prescription get the prescription, and I tell them honestly what they are leaving on the table.
If you have noticed changes in erectile function — particularly if you are under 60 and the change is recent — the most useful next step is a comprehensive workup that treats the symptom and the underlying vascular picture as one problem rather than two. We see new patients on this presentation every week at the Columbus location and the Warner Robins location. Bring any recent lab work, any cardiac evaluations you have had, and a list of current medications. We will start there.
Medical disclaimer: This article is for educational purposes only and does not constitute medical advice. Individual clinical decisions should be made in consultation with a qualified healthcare provider following appropriate evaluation. References to specific treatments, dosing, or protocols are informational.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
Ready to talk it through with a clinician?
Book online or call either Georgia location. Every visit starts with a consultation.